MarketPeel
Insider Trading Intelligence
Pricing
…
AL

Arch Venture Fund X, L.p.

NMRA
10% OWNER · NEUMORA THERAPEUTICS, INC. · CIK 0001757011
FILING MIX · LIFETIME51%/49%
BUYS
22
SELLS
21
TOTAL VALUE
$73.30M
COMPANIES
4
ACTIVE SINCE
Feb 2021
HOLDINGS NOW
22,944,594
AVG SELL PX
—
TRADE KIND
SHOWING 43 / 43
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 4 pending
Forward-return performance of every backtestable P/S trade by Arch Venture Fund X, L.p., measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+66.67%+14.71%+0.16%+14.55%+9.71%—
14d6+66.67%+10.86%+0.51%+10.34%+7.22%—
30d6+33.33%+8.05%+1.09%+6.96%-11.84%—
60d6+66.67%+11.43%+3.23%+8.21%+14.29%—
90d6+66.67%+16.82%+5.26%+11.56%+6.95%—
180d6+16.67%-13.73%+8.71%-22.44%-22.74%—
1y6(2 pending)+25.00%-41.15%+23.84%-64.99%-73.57%—
2y6(2 pending)+0.00%-54.25%+43.03%-97.28%-86.32%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NMRA · 6,046,907 shares · as of Oct 27, 2025
03,051,3456,102,6909,154,03412,205,37920242025SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
FLOW · 22 buys / 21 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
1,915,700$2.61$5.00M6,046,907Oct 27, 2025Oct 29, 2025 ↗View →
PRME
PRIME MEDICINE, INC.
PURCHASE
3,030,300$3.30$10.00M6,230,300Aug 1, 2025Aug 1, 2025 ↗View →
PRME
PRIME MEDICINE, INC.
PURCHASE
3,200,000$6.25$20.00M3,200,000Feb 15, 2024Feb 20, 2024 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
727,272$5.50$4.00M12,446,022Feb 8, 2024Feb 12, 2024 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
363,637$5.50$2.00M10,667,387Feb 8, 2024Feb 12, 2024 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
1,176,593——2,321,566Dec 8, 2023Dec 12, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
703,061——1,387,228Dec 8, 2023Dec 12, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
6,895,021——12,205,379Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
6,576,400——11,886,758Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
1,144,973——1,144,973Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
6,576,400——0Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
2,124,143——2,124,143Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
1,500,000$17.00$25.50M3,624,143Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
6,895,021——0Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
684,167——684,167Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
1,144,973——0Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
2,124,143——0Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
684,167——0Sep 19, 2023Sep 19, 2023 ↗View →
PRME
PRIME MEDICINE, INC.
PURCHASE
5,728,297——5,728,297Oct 24, 2022Oct 26, 2022 ↗View →
PRME
PRIME MEDICINE, INC.
SALE
16,666,667——0Oct 24, 2022Oct 26, 2022 ↗View →
PRME
PRIME MEDICINE, INC.
SALE
16,666,664——0Oct 24, 2022Oct 26, 2022 ↗View →
PRME
PRIME MEDICINE, INC.
SALE
1,141,474——0Oct 24, 2022Oct 26, 2022 ↗View →
PRME
PRIME MEDICINE, INC.
PURCHASE
400,000$17.00$6.80M6,128,297Oct 24, 2022Oct 26, 2022 ↗View →
ERAS
ERASCA, INC.
SALE
3,400,000——0Jul 20, 2021Jul 20, 2021 ↗View →
ERAS
ERASCA, INC.
PURCHASE
5,527,777——5,527,777Jul 20, 2021Jul 20, 2021 ↗View →
ERAS
ERASCA, INC.
SALE
2,100,000——0Jul 20, 2021Jul 20, 2021 ↗View →
ERAS
ERASCA, INC.
SALE
1,133,333——0Jul 20, 2021Jul 20, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
5,687,500——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
2,343,750——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
10,156,250——10,301,250Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
11,718,750——11,718,750Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
781,250——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
10,156,250——10,303,750Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
3,687,500——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
9,375,000——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
3,687,500——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
5,687,500——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
2,343,750——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
10,156,250——10,303,750Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
11,718,750——11,718,750Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
10,156,250——10,301,250Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
9,375,000——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
781,250——0Feb 8, 2021Feb 10, 2021 ↗View →
Other insiders · NMRA
Loading peer insiders…
About this filer
CIK 0001757011
ROLE
10% Owner
PRIMARY
NMRA
COMPANIES
4
ACTIVE SINCE
Feb 2021
MARKETPEEL · /INSIDER/0001757011DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback